Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 25, 2024
Question-based drug development and the value of novel treatments
Saco J de Visser, Adam F Cohen
Frontiers in Medicine
|
March 7, 2019
Corrigendum: Controlled Human Infections As a Tool to Reduce Uncertainty in Clinical Vaccine Development
Meta Roestenberg, Ingrid M C Kamerling, Saco J de Visser
Frontiers in Medicine
|
November 14, 2018
Controlled Human Infections As a Tool to Reduce Uncertainty in Clinical Vaccine Development
Meta Roestenberg, Ingrid M C Kamerling, Saco J de Visser
Nature Biotechnology
|
December 29, 2019
Integrating scientific considerations into R&D project valuation
Saco J de Visser, Adam F Cohen, Marcel J H Kenter
British Journal of Clinical Pharmacology
|
January 3, 2018
Gender differences in clinical registration trials: is there a real problem?
Geert Labots, Aubrey Jones, Saco J de Visser, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 15, 2022
Author Reply
Sibren van den Berg, Saco J de Visser, Lonneke Timmers, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
November 4, 2024
Drug pricing models, no 'one-size-fits-all' approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape
Evert A Manders, Sibren van den Berg, Saco J de Visser, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
February 7, 2026
Repurposing biosimilars, rethinking costs: a framework for sustainable drug pricing for repurposed bevacizumab for intravitreal injections
Evert A Manders, Vincent van Der Wel, Reinier Schlingemann, et al.
Drug Discovery Today
|
February 21, 2026
Tracing the path of non-industry-driven medicine development for rare diseases through regulatory interactions at the European Medicines Agency
Noa Rosenberg, Carla E M Hollak, V A Haverhoek, et al.
Clinical Pharmacology and Therapeutics
|
October 19, 2002
Concentration-effect relationships of two rilmenidine single-dose infusion rates in hypertensive patients
Saco J de Visser, Jeroen-Paul van der Post, Loyd Nanhekhan, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
Expert Review of Pharmacoeconomics & Outcomes Research
|
October 25, 2024
Question-based drug development and the value of novel treatments
Saco J de Visser, Adam F Cohen
Frontiers in Medicine
|
March 7, 2019
Corrigendum: Controlled Human Infections As a Tool to Reduce Uncertainty in Clinical Vaccine Development
Meta Roestenberg, Ingrid M C Kamerling, Saco J de Visser
Frontiers in Medicine
|
November 14, 2018
Controlled Human Infections As a Tool to Reduce Uncertainty in Clinical Vaccine Development
Meta Roestenberg, Ingrid M C Kamerling, Saco J de Visser
Nature Biotechnology
|
December 29, 2019
Integrating scientific considerations into R&D project valuation
Saco J de Visser, Adam F Cohen, Marcel J H Kenter
British Journal of Clinical Pharmacology
|
January 3, 2018
Gender differences in clinical registration trials: is there a real problem?
Geert Labots, Aubrey Jones, Saco J de Visser, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 15, 2022
Author Reply
Sibren van den Berg, Saco J de Visser, Lonneke Timmers, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
November 4, 2024
Drug pricing models, no 'one-size-fits-all' approach: a systematic review and critical evaluation of pricing models in an evolving pharmaceutical landscape
Evert A Manders, Sibren van den Berg, Saco J de Visser, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care
|
February 7, 2026
Repurposing biosimilars, rethinking costs: a framework for sustainable drug pricing for repurposed bevacizumab for intravitreal injections
Evert A Manders, Vincent van Der Wel, Reinier Schlingemann, et al.
Drug Discovery Today
|
February 21, 2026
Tracing the path of non-industry-driven medicine development for rare diseases through regulatory interactions at the European Medicines Agency
Noa Rosenberg, Carla E M Hollak, V A Haverhoek, et al.
Clinical Pharmacology and Therapeutics
|
October 19, 2002
Concentration-effect relationships of two rilmenidine single-dose infusion rates in hypertensive patients
Saco J de Visser, Jeroen-Paul van der Post, Loyd Nanhekhan, et al.
Page
of 2